| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 151, 343-351, Copyright © 1997 by American Society for Investigative Pathology
REGULAR ARTICLES |
S Pittaluga, I Wiodarska, K Pulford, E Campo, SW Morris, H Van den Berghe and C De Wolf-Peeters
Department of Pathology, University of Leuven, Belgium.
Anaplastic large cell lymphoma (ALCL) is a heterogeneous group of diseases by morphology, phenotype, genotype, and clinical presentation. Using a new monoclonal antibody (ALK1) that recognizes the native anaplastic lymphoma kinase (ALK) protein as well as the fusion product of the t(2;5)(p23;q35), nucleophosmin (NPM)/ALK, we investigated for ALK expression cases diagnosed as ALCL as well as lympho-proliferative disorders possessing overlapping features with ALCL. Thirteen cases showed cytoplasmic staining of the neoplastic cells. These cases were characterized by a fairly uniform morphology and occurred in children and young adults as a systemic disease. All other cases comprising T or null ALCL (17 cases), B ALCL (8 cases), Hodgkin's disease (HD) (15 cases), HD-like ALCL (23 cases), and lymphomatoid papulosis (9 cases), were negative for ALK expression. Translocation t(2;5)(p23;q35) was found by classical cytogenetics or interphase fluorescence in situ hybridization in 8 of the ALK1-positive cases and by reverse transcription-polymerase chain reaction in 1 other case. Two additional ALK1-positive cases with an abnormal karyotype, but without t(2;5)(p23;q35), showed by fluorescence in situ hybridization analysis a cryptic NPM/ALK gene fusion caused by an insertion of ALK near NPM in one case and a translocation of ALK to 2q35 as a result of an indiscernible inv(2)(p23q35) in the other. The latter variant translocation points to a localization of an unknown gene at 2q35 that, like NPM, might deregulate ALK and be involved in the pathogenesis of ALCL. In summary, immunohistochemistry with ALK1 antibody allows the identification of a distinct subgroup within the ALCL of T or null phenotype that is associated with 2p23 abnormalities and lacks the marked histological pleomorphism described in ALCL in general. Whereas immunostaining is the most sensitive method to identify this group, it does not help to additionally clarify the relationship among ALCL, HD, and HD-like ALCL.
This article has been cited by other articles:
 |
|
 |
|
  R Rust, G Harms, T Blokzijl, M Boot, A Diepstra, J Kluiver, L Visser, S-C Peh, M Lim, W A Kamps, et al. High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma J. Clin. Pathol., May 1, 2005; 58(5): 520 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Janik, J. C. Morris, S. Pittaluga, K. McDonald, M. Raffeld, E. S. Jaffe, N. Grant, M. Gutierrez, T. A. Waldmann, and W. H. Wilson Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma Blood, November 15, 2004; 104(10): 3355 - 3357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Z. Rassidakis, A. Goy, L. J. Medeiros, Y. Jiang, A. Thomaides, Y. Remache, F. Cabanillas, A. H. Sarris, and F. Gilles Prognostic Significance of MUC-1 Expression in Systemic Anaplastic Large Cell Lymphoma Clin. Cancer Res., June 1, 2003; 9(6): 2213 - 2220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Kutok and J. C. Aster Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma J. Clin. Oncol., September 1, 2002; 20(17): 3691 - 3702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Falini and D. Y. Mason Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry Blood, January 15, 2002; 99(2): 409 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhang, P. N. Raghunath, L. Xue, M. Majewski, D. F. Carpentieri, N. Odum, S. Morris, T. Skorski, and M. A. Wasik Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma J. Immunol., January 1, 2002; 168(1): 466 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. O. Jacobson and L. de Leval Case 34-2001- A 54-Year-Old Woman with Multiple Sclerosis, Prolonged Fever, and Skin Nodules N. Engl. J. Med., November 8, 2001; 345(19): 1409 - 1415. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Z. Rassidakis, A. H. Sarris, M. Herling, R. J. Ford, F. Cabanillas, T. J. McDonnell, and L. J. Medeiros Differential Expression of BCL-2 Family Proteins in ALK-Positive and ALK-Negative Anaplastic Large Cell Lymphoma of T/Null-Cell Lineage Am. J. Pathol., August 1, 2001; 159(2): 527 - 535. [Abstract] [Full Text]
|
|
|
|
|
|
K. Seidemann, M. Tiemann, M. Schrappe, E. Yakisan, I. Simonitsch, G. Janka-Schaub, W. Dorffel, M. Zimmermann, G. Mann, H. Gadner, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90 Blood, June 15, 2001; 97(12): 3699 - 3706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Maes, V. Vanhentenrijk, I. Wlodarska, J. Cools, B. Peeters, P. Marynen, and C. De Wolf-Peeters The NPM-ALK and the ATIC-ALK Fusion Genes Can Be Detected in Non-Neoplastic Cells Am. J. Pathol., June 1, 2001; 158(6): 2185 - 2193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Stein, H.-D. Foss, H. Durkop, T. Marafioti, G. Delsol, K. Pulford, S. Pileri, and B. Falini CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features Blood, December 1, 2000; 96(12): 3681 - 3695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, T. Yoshino, H. Yamabe, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype Blood, November 1, 2000; 96(9): 2993 - 3000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. de Wolf-Peeters and R. Achten Anaplastic large cell lymphoma: what's in a name? J. Clin. Pathol., June 1, 2000; 53(6): 407 - 408. [Full Text] [PDF]
|
|
|
|
|
|
R. L t. Berge, J. J Oudejans, G.-J. Ossenkoppele, K. Pulford, R. Willemze, B. Falini, A. Chott, and C. J L M Meijer ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination J. Clin. Pathol., June 1, 2000; 53(6): 445 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Touriol, C. Greenland, L. Lamant, K. Pulford, F. Bernard, T. Rousset, D. Y. Mason, and G. Delsol Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like) Blood, May 15, 2000; 95(10): 3204 - 3207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. B. Colleoni, J. A. Bridge, B. Garicochea, J. Liu, D. A. Filippa, and M. Ladanyi ATIC-ALK: A Novel Variant ALK Gene Fusion in Anaplastic Large Cell Lymphoma Resulting from the Recurrent Cryptic Chromosomal Inversion, inv(2)(p23q35) Am. J. Pathol., March 1, 2000; 156(3): 781 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hernandez, M. Pinyol, S. Hernandez, S. Bea, K. Pulford, A. Rosenwald, L. Lamant, B. Falini, G. Ott, D. Y. Mason, et al. TRK-Fused Gene (TFG) Is a New Partner of ALK in Anaplastic Large Cell Lymphoma Producing Two Structurally Different TFG-ALK Translocations Blood, November 1, 1999; 94(9): 3265 - 3268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rosenwald, G. Ott, K. Pulford, T. Katzenberger, J. Kuhl, J. Kalla, M. M. Ott, D. Y. Mason, and H. K. Muller-Hermelink t(1;2)(q21;p23) and t(2;3)(p23;q21): Two Novel Variant Translocations of the t(2;5)(p23;q35) in Anaplastic Large Cell Lymphoma Blood, July 1, 1999; 94(1): 362 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Griffin, A. L. Hawkins, C. Dvorak, C. Henkle, T. Ellingham, and E. J. Perlman Recurrent Involvement of 2p23 in Inflammatory Myofibroblastic Tumors Cancer Res., June 1, 1999; 59(12): 2776 - 2780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Pulford, B. Falini, J. Cordell, A. Rosenwald, G. Ott, H.-K. Muller-Hermelink, K. A. MacLennan, L. Lamant, A. Carbone, E. Campo, et al. Biochemical Detection of Novel Anaplastic Lymphoma Kinase Proteins in Tissue Sections of Anaplastic Large Cell Lymphoma Am. J. Pathol., June 1, 1999; 154(6): 1657 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Gascoyne, P. Aoun, D. Wu, M. Chhanabhai, B. F. Skinnider, T. C. Greiner, S. W. Morris, J. M. Connors, J. M. Vose, D. S. Viswanatha, et al. Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma Blood, June 1, 1999; 93(11): 3913 - 3921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lamant, N. Dastugue, K. Pulford, G. Delsol, and B. Mariame A New Fusion Gene TPM3-ALK in Anaplastic Large Cell Lymphoma Created by a (1;2)(q25;p23) Translocation Blood, May 1, 1999; 93(9): 3088 - 3095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. ten Berge, D. F. Dukers, J. J. Oudejans, K. Pulford, G. J. Ossenkoppele, D. de Jong, J. F.M.M. Misere, and C. J.L.M. Meijer Adverse Effects of Activated Cytotoxic T Lymphocytes on the Clinical Outcome of Nodal Anaplastic Large Cell Lymphoma Blood, April 15, 1999; 93(8): 2688 - 2696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Cordell, K. A.F. Pulford, B. Bigerna, G. Roncador, A. Banham, E. Colombo, P.-G. Pelicci, D. Y. Mason, and B. Falini Detection of Normal and Chimeric Nucleophosmin in Human Cells Blood, January 15, 1999; 93(2): 632 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Wlodarska, C. De Wolf-Peeters, B. Falini, G. Verhoef, S. W. Morris, A. Hagemeijer, and H. Van denBerghe The Cryptic inv(2)(p23q35) Defines a New Molecular Genetic Subtype of ALK-Positive Anaplastic Large-Cell Lymphoma Blood, October 15, 1998; 92(8): 2688 - 2695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Falini, B. Bigerna, M. Fizzotti, K. Pulford, S. A. Pileri, G. Delsol, A. Carbone, M. Paulli, U. Magrini, F. Menestrina, et al. ALK Expression Defines a Distinct Group of T/Null Lymphomas (""ALK Lymphomas"") with a Wide Morphological Spectrum Am. J. Pathol., September 1, 1998; 153(3): 875 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Beylot-Barry, A. Groppi, B. Vergier, K. Pulford, J.P. Merlio, and t. French Study Group of Cutaneous Lymphoma Characterization of t(2;5) Reciprocal Transcripts and Genomic Breakpoints in CD30+ Cutaneous Lymphoproliferations Blood, June 15, 1998; 91(12): 4668 - 4676. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
